← Back to Clinical Trials
Recruiting NCT04524585

NCT04524585 Partial Neuromuscular Blockade in Acute Hypoxemic Respiratory Failure

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04524585
Status Recruiting
Phase
Sponsor University Health Network, Toronto
Condition Respiratory Insufficiency
Study Type INTERVENTIONAL
Enrollment 23 participants
Start Date 2020-10-01
Primary Completion 2026-12-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Cisatracurium

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 23 participants in total. It began in 2020-10-01 with a primary completion date of 2026-12-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

PNEUMA is a preliminary safety and feasibility trial of a novel approach to the titration of neuromuscular blockade (NMB) to safe spontaneous breathing in patients with moderate to severe acute hypoxemic respiratory failure (AHRF) supported with invasive mechanical ventilation.

Eligibility Criteria

Inclusion Criteria: Patients supported on invasive mechanical ventilation for moderate to severe AHRF (PaO2/FiO2 \< 150 mm Hg or FiO2 ≥ 60% with an SpO2 ≤ 97% or receiving venovenous extracorporeal membrane oxygenation) Exclusion Criteria: 1. Contraindication to neuromuscular blockade (allergy, history of malignant hyperthermia) 2. Contraindication to ulnar nerve stimulation (bilateral peripheral neuropathy, skin burns on both wrists) 3. Previous history of a formally diagnosed neuromuscular disorder

Contact & Investigator

Central Contact

Glauco M. Plens, MD, PhD

✉ glauco.plens@uhn.ca

📞 4373299590

Principal Investigator

Ewan Goligher, MD, PhD

PRINCIPAL INVESTIGATOR

University Health Network, Toronto

Frequently Asked Questions

Who can join the NCT04524585 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Respiratory Insufficiency. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04524585 currently recruiting?

Yes, NCT04524585 is actively recruiting participants. Contact the research team at glauco.plens@uhn.ca for enrollment information.

Where is the NCT04524585 trial being conducted?

This trial is being conducted at Toronto, Canada.

Who is sponsoring the NCT04524585 clinical trial?

NCT04524585 is sponsored by University Health Network, Toronto. The principal investigator is Ewan Goligher, MD, PhD at University Health Network, Toronto. The trial plans to enroll 23 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology